BLGO — BioLargo Income Statement
0.000.00%
Last trade - 00:00- $60.97m
- $57.94m
- $17.78m
- 31
- 20
- 44
- 22
Annual income statement for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.43 | 2.53 | 5.88 | 12.2 | 17.8 |
| Cost of Revenue | |||||
| Gross Profit | 1.23 | 1.1 | 2.86 | 6.15 | 7.85 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 10.5 | 9.31 | 11.1 | 16.8 | 22 |
| Operating Profit | -8.03 | -6.78 | -5.22 | -4.58 | -4.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.7 | -6.89 | -5.13 | -4.65 | -4.35 |
| Net Income After Taxes | -9.7 | -6.89 | -5.13 | -4.65 | -4.35 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.43 | -7.08 | -4.47 | -3.5 | -2.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.43 | -7.08 | -4.47 | -3.5 | -2.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.041 | -0.027 | -0.017 | -0.011 | -0.008 |